The Institute of Cancer Research (ICR), London, UK is over 100 years old and work closely with the Royal Marsden Hospital, in London. Together they are one of the four top-rated facilities for cancer research and treatment, globally. Over the years ICR has been responsible for many life-enhancing discoveries and treatments. Some significant ones are:
- They were the first to discover the carcinogens in cigarettes, from 1920
- First in Europe to develop chemotherapy drugs, from 1950
- Provided conclusive evidence that cancer is caused due to DNA damage, from 1960
- Discovered the fundamental basis for cancer immunotherapy, in 1960
- Led major practice-changing clinical trials in radiotherapy and imaging, from 1986
- Discovered a gene that enabled families with a breast cancer history to be assessed for future risk, from 1990
- Discovered and developed a major life-extending drug for prostate cancer, in 2012
ICR is funded through grants, royalty income, education council funding, and donations. Many parent-led organizations fund specific areas of research, especially those where no government grants or royalties are available. Normally grants are available once research reaches a breakthrough stage, but the initial funding is always a challenge. Hence, there is a large dependency on fundraising and support from different sources. In 2016-17, donations contributed to around 13% of the total income for ICR. The Rudy A Menon Foundation has been funding research in ICR by Prof. Chris Jones, on rare and inoperable brain cancers, such as Gliomatosis Cerebri, from 2014.
Prof. Chris Jones at ICR leads a team that does research on gliomas, which is a fatal and often inoperable form of brain tumor, in children. He is a Fellow of the Royal College of Pathologists and is the Biology Lead for the International Society for Paediatric Oncology European (SIOPE) High-Grade Glioma Working Group. One of the strains that they are specifically researching on covers Gliomatosis Cerebri, which is one of the least understood forms of brain cancer, and mainly affects children and young adults.
Join the advocacy and become part of the community that was established to support groundbreaking research in finding a cure for Gliomatosis Cerebri. Partners are either family touched by Gliomatosis Cerebri or foundations supporting the same cause. Click below to learn how to join the community.